These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1885750)

  • 41. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity.
    Virk RK; Jayakumar J; Mendenhall IH; Moorthy M; Lam P; Linster M; Lim J; Lin C; Oon LLE; Lee HK; Koay ESC; Vijaykrishna D; Smith GJD; Su YCF
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):619-628. PubMed ID: 31843889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
    Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospects for broadly protective influenza vaccines.
    Treanor JJ
    Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Seroconversion after vaccine with trivalent influenza vaccine during the epidemic season 1990/1 in Poland].
    Brydak L; Rudnicka H; Gut W; Magdzik W; Kańtoch M
    Przegl Epidemiol; 1992; 46(3):221-9. PubMed ID: 1296247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunogenicity and safety of domestic slit influenza vaccine].
    Zhu XJ; Zhang ZL; Li H; Su X; Guo XH; Chen W; Kou M; Duan WP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jul; 25(7):644. PubMed ID: 15308057
    [No Abstract]   [Full Text] [Related]  

  • 52. Significant circulation of influenza B viruses mismatching the recommended vaccine-lineage in South Korea, 2007-2014.
    Noh JY; Choi WS; Song JY; Lee HS; Lim S; Lee J; Seo YB; Lee JS; Wie SH; Jeong HW; Heo JY; Kim YK; Park KH; Kim SW; Lee SH; Lee JH; Kim DH; Woo SI; Lim CS; Cho KS; Cheong HJ; Kim WJ
    Vaccine; 2018 Aug; 36(35):5304-5308. PubMed ID: 30057284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe.
    Broberg E; Melidou A; Prosenc K; Bragstad K; Hungnes O;
    Euro Surveill; 2016; 21(13):. PubMed ID: 27074657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular epidemiology of influenza B virus and implications in immunization strategy, Southern Brazil.
    Lapinscki B; Pereira LA; Nogueira MB; Vidal LR; Riediger I; Debur MC; Presibella M; Raboni SM
    Vaccine; 2018 Jan; 36(1):107-113. PubMed ID: 29174679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.
    Kissling E; Valenciano M; Pozo F; Vilcu AM; Reuss A; Rizzo C; Larrauri A; Horváth JK; Brytting M; Domegan L; Korczyńska M; Meijer A; Machado A; Ivanciuc A; Višekruna Vučina V; van der Werf S; Schweiger B; Bella A; Gherasim A; Ferenczi A; Zakikhany K; O Donnell J; Paradowska-Stankiewicz I; Dijkstra F; Guiomar R; Lazar M; Kurečić Filipović S; Johansen K; Moren A;
    Influenza Other Respir Viruses; 2018 Jul; 12(4):423-437. PubMed ID: 29125681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
    Kikuta K; Hirabayashi Y; Nagamine T; Aizawa C; Ueno Y; Oya A; Kurata T; Tamura S
    Vaccine; 1990 Dec; 8(6):595-9. PubMed ID: 1965078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old].
    Grigor'eva EP; Rekstin AR; Rudenko LG; Ramirez A; Barro M; Lisovskaia KV; Klimov AI; Aleksandrova GI
    Vopr Virusol; 1994; 39(1):26-9. PubMed ID: 8160445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.